Sigyn Therapeutics Appoints Medical Technology Expert to Scientific Advisory Board
TL;DR
Sigyn Therapeutics gains competitive edge by appointing Dr. Christoph Zaba to its advisory board, leveraging his expertise to advance cardiovascular disease treatments.
Sigyn Therapy uses whole blood adsorption on dialysis machines to reduce Lp(a) and LDL-C levels, potentially cutting cardiovascular events by 55-98%.
Sigyn's technology expands access to life-saving cardiovascular treatments from 60 specialized centers to 7,500 dialysis clinics, improving global health outcomes.
Sigyn Therapeutics combines dialysis and apheresis to simultaneously target cholesterol and inflammation, pioneering a novel approach to combat heart disease.
Found this article helpful?
Share it with your network and spread the knowledge!
Sigyn Therapeutics has appointed Dr. Christoph Zaba to its Scientific Advisory Board, bringing extensive experience in medical technology and extracorporeal therapies to the company's development efforts. Dr. Zaba previously directed global product management in therapeutic apheresis at Fresenius Medical Care, advancing treatments across multiple medical specialties including nephrology, dermatology, neurology, and cardiovascular medicine.
The appointment comes as Sigyn Therapeutics advances Sigyn Therapy™, a whole blood adsorption technology designed to reduce lipoprotein(a) and low-density lipoprotein cholesterol in the bloodstream while simultaneously targeting inflammatory molecules that fuel cardiovascular disease progression. Cardiovascular disease remains the leading cause of global deaths, making innovative treatment approaches critically important.
Studies of lipoprotein apheresis, the commercial name for extracorporeal removal of these pathogenic lipoproteins, have reported 55% to 98% reductions in major adverse cardiovascular events. While the therapeutic benefit is well-established, treatment access is severely limited with fewer than 60 specialized apheresis centers in the United States. Sigyn Therapy™ is specifically designed for use on dialysis machines already located in approximately 7,500 U.S. dialysis clinics, potentially dramatically expanding treatment accessibility.
On September 3rd, the company disclosed plans to commence a multi-site clinical feasibility study of Sigyn Therapy™ in high-risk cardiovascular disease subjects with end-stage renal disease. The successful completion of this feasibility study could set the stage for a pivotal efficacy study necessary to obtain potential market clearance for cardiovascular disease treatment. More information about Dr. Zaba's background and expertise can be found at https://www.sigyntherapeutics.com/about/scientific-advisory-board.
Beyond cardiovascular applications, Sigyn Therapeutics is also developing dialysis-like cancer therapies including ImmunePrep™ to optimize immunotherapeutic antibody delivery, ChemoPrep™ to enhance targeted chemotherapy delivery, and ChemoPure™ to reduce chemotherapy toxicity. The company plans to advance these cancer treatment candidates through joint venture development relationships, expanding its pipeline of extracorporeal treatment technologies.
Curated from NewMediaWire
